A 52-year-old woman with advanced recurrent endometrial carcinoma shows microsatellite instability-high (MSI-H) status on molecular testing. She has progressed after platinum-based chemotherapy. Which targeted therapy is FDA-approved and guideline-recommended for this molecular profile?

• A Bevacizumab
• B Trastuzumab
• C Olaparib
• D Pembrolizumab ✓

Explanation

Pembrolizumab, a PD-1 inhibitor, is FDA-approved for MSI-H or dMMR solid tumors regardless of tissue of origin (tissue-agnostic approval based on KEYNOTE-158). Dostarlimab is also approved specifically for dMMR endometrial cancer (GARNET trial). Bevacizumab is anti-angiogenic but not specific to MSI-H. Olaparib targets BRCA-mutated tumors. Trastuzumab is for HER2-positive breast and gastric cancers.

Reference: Harrison's Principles of Internal Medicine, 21st ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.